Brief: Sanofi: EC Approves Sarclisa

Sanofi SA

08/06/2026 06:11

June 8 (Reuters) - Sanofi SA SASY.PA:
EUROPEAN COMMISSION APPROVES SARCLISA SUBCUTANEOUS FOR MULTIPLE MYELOMA ACROSS ALL EXISTING IV INDICATIONS
SARCLISA FIRST ANTICANCER THERAPY IN EU ADMINISTERED VIA ON-BODY INJECTOR AND MANUAL SC INJECTION
70% OF PATIENTS REPORTED SATISFACTION WITH SARCLISA SC VIA OBI IN IRAKLIA PHASE 3 STUDY
SARCLISA SUBCUTANEOUS WITH ON-BODY INJECTOR SHOWS EFFICACY ACROSS ALL APPROVED IV INDICATIONS
Source text: nGNE1fFf52
Further company coverage: SASY.PA

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))